Jacobs Levy Equity Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-2,000
| Closed | -$511K | – | 1142 |
|
|
2021
Q2 | $511K | Sell |
2,000
-3,558
| -64% | -$909K | ﹤0.01% | 856 |
|
|
2021
Q1 | $1.48M | Sell |
5,558
-1,230
| -18% | -$327K | 0.01% | 652 |
|
|
2020
Q4 | $2.5M | Sell |
6,788
-2,902
| -30% | -$1.07M | 0.02% | 524 |
|
|
2020
Q3 | $2.37M | Buy |
9,690
+3,586
| +59% | +$876K | 0.02% | 492 |
|
|
2020
Q2 | $1.76M | Buy |
6,104
+3,305
| +118% | +$952K | 0.02% | 553 |
|
|
2020
Q1 | $571K | Buy |
2,799
+2,087
| +293% | +$426K | 0.01% | 732 |
|
|
2019
Q4 | $318K | Sell |
712
-10
| -1% | -$4.47K | ﹤0.01% | 845 |
|
|
2019
Q3 | $222K | Buy |
+722
| New | +$222K | ﹤0.01% | 825 |
|
|
2016
Q2 | – | Sell |
-498
| Closed | -$251K | – | 1246 |
|
|
2016
Q1 | $251K | Buy |
+498
| New | +$251K | 0.01% | 919 |
|